Transatlantic sister companies Amyndas Pharmaceuticals S.A. and Amyndas Pharmaceuticals LLC are developing therapies to treat complement-mediated disorders that could be more potent than other complement inhibitors, potentially opening up new indications.

Lead candidate Amanden comes from a class of synthetic analogs of the peptidic complement 3 (C3) inhibitor compstatin, which the company calls super compstatins.